Hanmi Pharmaceutical has announced that a delegation of Canadian CEOs from 10 biopharmaceutical companies, including Atuka, Genvira Biosciences, and iProgen, along with key officials, visited Hanmi Pharmaceutical's Pyeongtaek Bio Plant on May 9th.
The Canadian Embassy in Korea had requested the delegation's visit to the Hanmi Pharmaceutical plant, which is known for its excellent manufacturing facilities among Korean companies participating in the "BIO KOREA 2023" event.
During the visit, Hanmi Pharm and the Canadian delegation engaged in discussions regarding the current state of the bio industry, both domestically and internationally. They also explored opportunities for open collaboration in areas of common interest.
The Canadian delegation had the opportunity to tour the Pyeongtaek plant and witness its state-of-the-art, large-scale manufacturing facilities, including incubators with a capacity of up to 12,500 liters. They showed a keen interest in Hanmi Pharmaceutical's R&D capabilities, particularly in the manufacturing and quality control of raw materials and finished drugs. The delegation was impressed by the comprehensive "end-to-end service" provided by Hanmi, which encompasses testing, approval data preparation, and more.
"Our company is currently in the growth stage, and it was immensely helpful to observe the overall process at the Hanmi Bio Plant and receive explanations," said Jiahu Wang, the founder of Genvira Biosciences, expressed gratitude for the visit. "The scale of the facility and the applied automation system, along with the flexibility to provide customized services according to customer needs, stood out to me."
“The entire process of biopharmaceutical production was impressive, and the technology, such as automatic warehouse, was excellent," said Stéphane Gagné, CEO of Immugenia. “From the fermentation stage, the first stage of biopharmaceutical production, it was remarkable that we could provide services tailored to the needs of our customers.”
Hanmi Pharm's Pyeongtaek bio plant boasts a production capacity of over 20 million prefilled syringes per year for finished drugs. Unlike other major domestic CMO (Contract Manufacturing Organization) companies that utilize animal cell culture-based facilities, the Pyeongtaek Plant employs microbial culture-based manufacturing facilities, enabling rapid and cost-effective mass production of biopharmaceuticals. The plant is also well-equipped to manufacture DNA and mRNA vaccines, which have gained significant attention following the global coronavirus pandemic.
"With the visit of the Canadian delegation to the Pyeongtaek plant, we anticipate enhanced mutual cooperation between Korean and Canadian biopharmaceutical companies," said an official from Hanmi Pharmaceutical.
